The Plain English Guide to Prostate Cancer: Everything a Man Should Know About the Walnut That Could Trip Him Up
Prostate
Here is a number that should get your attention: about 1 in 9 men will be diagnosed with prostate cancer at some point in life. It is the most commonly diagnosed non-skin cancer in American men and the second leading cause of cancer death in men.
Here is another number that should get your attention in the opposite direction: when prostate cancer is caught early, the five year survival rate approaches 100%. Read that again. Caught early, almost nobody dies of this thing.
The whole game, then, is about catching it early, treating it wisely (which sometimes means not treating it at all), and not getting scared into either ignoring it or overdoing it. This guide walks through all of that in plain language.
What Is the Prostate?
The prostate is a walnut-sized gland that sits just below the bladder and wraps around the urethra (the tube that carries urine out). Its main job is making fluid that becomes part of semen. Most of the time it goes about its business quietly, like a polite roommate. But sometimes the cells inside it start growing out of control, and that is prostate cancer.
Part One: Who Gets Prostate Cancer and Why
The Big Three Risk Factors You Cannot Change
Age. Prostate cancer is rare before age 40. The risk climbs steeply after 50, and the median age of death from prostate cancer is 80. This is largely a disease of older men, though there are exceptions.
Family history. Having a father or brother with prostate cancer roughly doubles your risk. Certain inherited gene changes, especially in BRCA2, can increase the risk of earlier and more aggressive disease. Yes, BRCA is the same gene people associate with breast cancer in women. The same family of mutations can travel through male relatives too.
Race and ethnicity. Black/African American men have higher incidence, earlier age at diagnosis, and higher mortality compared to white men. Research shows this is related to a higher rate of preclinical cancer plus social determinants of health, not to biological differences in the tumors themselves. When Black patients receive equal treatment, outcomes match those of white patients.
Other Risk Factors
Agent Orange exposure in many Vietnam War veterans is associated with higher risk of aggressive prostate cancer.
Taller height has a modest association with aggressive disease.
Obesity is consistently linked to advanced prostate cancer and worse outcomes after diagnosis.
Smoking is associated with higher prostate cancer mortality.
Germline mutations in DNA repair genes (BRCA1, BRCA2, and others) are found in about 12% of men with metastatic prostate cancer.
The Genetics Caveat
Prostate cancer has among the highest heritability of all common cancers. That is a fancy way of saying genes matter more here than for most other cancers. You did not pick your parents. That said, lifestyle still plays a real role, especially in how aggressive the disease becomes if it shows up.
Part Two: Diet and Lifestyle
Foods and Habits That May LOWER Risk
Cooked tomatoes and lycopene. One study found men eating canned or cooked tomatoes more than four times a week had a 28% lower risk of prostate cancer. Lycopene, the red pigment in tomatoes, watermelon, and pink grapefruit, appears to be the active ingredient. Cooking makes it easier for the body to absorb. So pasta sauce, salsa, and tomato soup count. The pizza defense is, surprisingly, partially valid.
Cruciferous vegetables. Broccoli, cauliflower, Brussels sprouts, kale. These have anti-inflammatory and possibly protective properties. Your grandmother was right.
Fish and omega-3 fatty acids. Some protective associations in the data. Salmon, sardines, and mackerel are good choices.
Physical activity. This one is striking. Mendelian randomization studies (which use genetics to estimate cause and effect more rigorously than ordinary observation) suggest that higher physical activity may reduce prostate cancer risk by as much as 51%. That is enormous for a single modifiable factor.
Soy foods. Tofu, soy milk, and edamame contain compounds called phytoestrogens that may modestly decrease risk. The evidence is still evolving but is generally favorable.
Foods and Habits That May INCREASE Risk
High dairy and calcium intake, especially calcium supplements exceeding 1,200 mg per day. Linked to higher risk of aggressive prostate cancer. Calcium from food appears less problematic than from pills.
Red and processed meats, particularly when grilled or charred. The high-temperature cooking produces compounds that may be carcinogenic. Burning the burger is not doing your prostate any favors.
High-fat diets, especially those rich in saturated fat.
Excessive alcohol consumption, particularly in combination with certain medications.
Supplements That Do NOT Work (and One That Made Things Worse)
The SELECT trial was a large, well-designed study that looked at vitamin E and selenium for prostate cancer prevention. The result was disappointing. There was no benefit, and vitamin E actually slightly increased the risk of prostate cancer. Do not take vitamin E or selenium supplements for prostate cancer prevention. Just do not.
Beta-carotene supplements: No proven benefit.
Vitamin D: Very mixed evidence, no compelling data either way.
The Bottom Line on Diet
Eat lots of vegetables and fruits (especially cooked tomatoes and cruciferous vegetables), choose fish over red meat, limit dairy and skip calcium supplements unless your doctor specifically recommends them, stay at a healthy weight, move your body regularly, and do not smoke. As a bonus, this is exactly the diet that protects your heart, which matters because cardiovascular disease is actually the leading cause of death in men with prostate cancer. The prostate may eventually be the headline, but the heart is often the story.
Part Three: How to Spot It (Hint: It Usually Hides)
The Sneaky Truth
Here is the frustrating part: early prostate cancer almost never causes symptoms. About 75% of newly diagnosed cases are localized (still inside the prostate), and these men usually feel perfectly fine. That is exactly why screening matters.
Symptoms that CAN occur (but usually mean either advanced cancer or a totally different problem):
Trouble starting or stopping urination
Weak urine stream
Frequent urination, especially at night (called nocturia)
Blood in urine or semen
Pain with ejaculation
When prostate cancer has spread (metastatic disease), the most common place it goes is the bones (82% of cases). That can cause:
Bone pain, especially in the back, hips, or pelvis
Fractures from weakened bones
Spinal cord compression (a medical emergency)
Fatigue and weight loss
Important reality check: Trouble peeing, getting up at night, and a weak stream are extremely common in older men. They are usually caused by benign prostatic hyperplasia (BPH), which is just the prostate getting bigger with age. Having these symptoms does not mean you have cancer. Most of the time, it just means you are getting older and your prostate is doing what prostates do.
Part Four: The Screening Conversation
What PSA Actually Is
PSA stands for prostate-specific antigen. It is a protein made by the prostate. A simple blood test measures the level in your blood. Higher levels can mean prostate cancer, but they can also be elevated by completely harmless conditions.
Think of PSA as a smoke detector. It tells you something might be going on, but it does not tell you whether there is an actual fire or just burnt toast. You still have to look.
What the Numbers Mean
PSA below 1 ng/mL: Very low risk. Retest every 2 to 4 years.
PSA 1 to 3 ng/mL: Low to moderate risk. Retest every 1 to 2 years.
PSA above 3 ng/mL (or above 4 ng/mL in older men): More evaluation recommended.
PSA above 10 ng/mL: Greater than 67% chance of prostate cancer.
Now the nuance, because medicine is never simple. About 15% of men with a PSA of 4.0 or below and a normal digital rectal exam still have prostate cancer found on biopsy. And 25% to 40% of men with a moderately elevated PSA (4 to 10 ng/mL) will see their PSA drop back to normal on a repeat test. That is why a single high PSA should always be repeated before anyone reaches for a biopsy needle.
When to Start Screening
The NCCN Guidelines (the National Comprehensive Cancer Network, which sets the standard) recommend:
Age 40 for high-risk individuals: Black/African American men, men with BRCA or other high-risk inherited mutations, men with a strong family history.
Age 45 for everyone else.
Continue through age 75 for most men with a life expectancy of 10 years or more.
After 75, screen only very healthy men with no other major medical problems.
The US Preventive Services Task Force recommends shared decision-making for men aged 55 to 69 and recommends against screening for men 70 and older. The two sets of guidelines disagree somewhat on age ranges, which is partly why the conversation with your doctor matters so much.
The Pros and Cons of Screening
Pros:
PSA screening prevents about 1.3 prostate cancer deaths per 1,000 men screened over 13 years.
It prevents about 3 cases of metastatic disease per 1,000 men screened.
A 2026 meta-analysis of 5 randomized trials with 721,607 participants and 11 to 23 years of follow-up provided high-certainty evidence that PSA screening reduces prostate cancer-specific mortality. This is a stronger evidence base than existed even a few years ago.
Early detection allows for active surveillance of low-risk cancers, sparing men from unnecessary treatment.
Cons:
False positives lead to anxiety and unnecessary biopsies.
Overdiagnosis: many detected cancers would never have caused symptoms or death.
Overtreatment: treating low-risk cancers can cause erectile dysfunction (2 in 3 men after surgery), urinary incontinence (1 in 5), and bowel problems.
No proven reduction in all-cause mortality, meaning the overall odds of dying from anything are not changed.
The right call is rarely "always screen" or "never screen." It is "have a real conversation with a doctor who knows your situation."
How to Bring It Up With a Doctor
It does not have to be awkward. Try one of these:
"I have been reading about prostate cancer screening. Can we talk about whether PSA testing makes sense for me?"
"My father had prostate cancer. Should I be getting tested?"
"I am 50 now. What do you think about prostate screening at this point?"
The key principle is shared decision-making. The doctor explains the potential benefits and harms. You decide based on your values and preferences. Nobody should have a PSA test ordered without being informed, and nobody should be denied information about screening either.
Part Five: The Diagnosis Process
If PSA is elevated or the digital rectal exam feels abnormal, the next steps usually look like this:
Repeat the PSA. Confirm that it is really elevated. As noted above, many PSAs that look high settle back to normal.
Multiparametric MRI (mpMRI). This is now a Category 1 recommendation, meaning the highest level of evidence. The MRI uses a scoring system called PI-RADS, rated 1 to 5, for how suspicious a lesion looks. A score of 1 or 2 means low suspicion, and a biopsy may be avoided. A score of 3 or higher means more evaluation is needed.
Consider biomarkers. Tests like percent-free PSA, PSA density, and other blood or urine markers can help decide whether a biopsy is truly needed. A newer urine test called MyProstateScore 2.0 (MPS2) measures genetic material from cancer cells shed into urine. It outperformed PSA, the older PCA3 test, and even the Prostate Health Index in detecting high-grade cancer.
Prostate biopsy. If suspicion is high, an image-guided biopsy is done. It can be done through the rectum (transrectal) or through the skin between the scrotum and rectum (transperineal). The transperineal approach has a lower risk of infection. MRI-targeted biopsy is preferred because it picks up clinically significant cancer more often while finding fewer insignificant ones.
Grading: What Gleason Scores and Grade Groups Mean
When cancer is found, the pathologist assigns a Gleason score based on how the cells look under the microscope. This has been simplified into Grade Groups:
Grade Group 1 (Gleason 6): Low grade, slow growing. Often managed with active surveillance.
Grade Group 2 (Gleason 3+4=7): Favorable intermediate risk.
Grade Group 3 (Gleason 4+3=7): Unfavorable intermediate risk.
Grade Group 4 (Gleason 8): High risk.
Grade Group 5 (Gleason 9 to 10): Very high risk.
The higher the Grade Group, the more aggressive the cancer.
Part Six: Common Misdiagnoses and Look-Alikes
Several harmless conditions can be confused with prostate cancer in both directions. Some get mistaken for cancer when they are not, and sometimes cancer gets dismissed as something else.
Conditions Commonly Confused WITH Prostate Cancer
Benign Prostatic Hyperplasia (BPH). The prostate naturally enlarges with age. BPH causes urinary symptoms nearly identical to those people worry are cancer (weak stream, frequency, getting up at night). BPH also raises PSA. The difference: BPH causes a smooth, symmetric enlargement on rectal exam, while cancer may cause a hard nodule. MRI and biopsy provide the real answer.
Prostatitis (inflammation or infection of the prostate). Can cause dramatic PSA elevations, pelvic pain, urinary symptoms, and even a suspicious-feeling prostate on exam. Acute bacterial prostatitis comes with fever, chills, and severe urinary symptoms. Chronic prostatitis or chronic pelvic pain syndrome causes long-term pelvic discomfort without infection. Critical point: if infection is suspected, PSA testing should be delayed until after treatment, because inflammation alone can spike PSA dramatically.
Normal anatomic structures on MRI. The anterior fibromuscular stroma, the central zone, and the veins around the prostate can all look suspicious on imaging. Post-biopsy bleeding can also create false-positive MRI findings. This is why experienced radiologists and high-quality MRI equipment matter.
Conditions Prostate Cancer Can Be Mistaken FOR
A man with bone pain from metastatic prostate cancer might first be diagnosed with arthritis or back problems.
Urinary symptoms from advanced prostate cancer might be blamed entirely on BPH.
Blood in the urine might trigger a workup for bladder or kidney problems while the prostate is overlooked.
How to Avoid Misdiagnosis
Always repeat an elevated PSA before going to biopsy.
Treat any suspected infection before interpreting PSA results.
Use MRI before biopsy whenever possible.
Know which medications can mess with PSA (next section).
Part Seven: Drugs That Change PSA (the Medication Trap)
This is critically important. Several common medications can raise or lower PSA, which can either mask a real cancer or trigger an unnecessary workup.
⚠️ If you take finasteride or dutasteride, your PSA result is artificially low. Tell every doctor who orders one.
These drugs (sold as Proscar, Avodart, Propecia, and others) cut PSA levels by about 50%, whether you're taking them for an enlarged prostate or for hair loss. That means a PSA reading that looks normal on paper might actually be elevated. The standard correction is to double the measured value to get the "true" number. Any confirmed rise in PSA while on these drugs, even if the number still looks normal, deserves a serious workup — not reassurance. The dangerous failure mode is a doctor seeing a "normal" PSA and missing an early cancer because nobody mentioned the medication.
Medications That LOWER PSA
5-alpha reductase inhibitors (finasteride/Proscar, dutasteride/Avodart): These drugs are used for BPH and hair loss. They cut PSA levels by about 50%. If a man is taking one, his PSA value should be doubled to get the "true" number. Any confirmed rise in PSA while on these drugs, even if the number looks normal on paper, deserves serious attention.
Statins: May reduce PSA by about 13% after 5 years of use.
Thiazide diuretics: May reduce PSA by about 26% after 5 years.
NSAIDs (ibuprofen, naproxen): May modestly reduce PSA by about 6% after 5 years.
Statins plus thiazide diuretics combined: Can reduce PSA by 36% after 5 years.
Estrogen therapy (in transgender women): Can drastically lower PSA. Rising PSA in this population deserves special attention since it has more weight when starting from a very suppressed baseline.
Medications That May RAISE PSA
Tamsulosin (Flomax): Used for BPH, may lead to PSA increases.
Testosterone replacement therapy: Stimulates prostate tissue and can raise PSA.
Medications That Affect the Effect of Other Drugs
Calcium channel blockers may minimize the PSA-lowering effect of statins.
The takeaway: tell every doctor every drug you take. The list matters more than people realize.
Part Eight: Treatment Options
Treatment depends on three things: the risk group (based on PSA, Gleason grade, and staging), life expectancy, and personal preference. There is no single right answer for everyone.
Active Surveillance: The Preferred Option for Most Low-Risk Disease
This is the preferred approach for most men with low-risk prostate cancer. It means watching the cancer closely with regular PSA tests, MRIs, and periodic biopsies, and only stepping up to treatment if the cancer shows signs of becoming more aggressive.
Why it works: In a study of 2,155 men with low-risk disease on active surveillance, at 10 years, less than 2% developed metastatic disease and less than 1% died of prostate cancer. About half never needed treatment at all.
The ProtecT trial randomized 1,643 men to active monitoring, surgery, or radiation. At 10 years, prostate cancer deaths were very low in all three groups (1.5%, 0.9%, and 0.7%), with no statistically significant difference. The men on active monitoring kept better quality of life along the way.
The NCCN Monitoring Schedule.
PSA: No more often than every 6 months
Digital rectal exam: No more often than every 12 months
Repeat prostate biopsy: Every 1 to 3 years (longer intervals after more than 3 years without progression)
Repeat MRI: No more often than every 12 months
Transition to simple observation when life expectancy drops below 10 years
Confirming Candidacy.
Confirmatory testing is strongly recommended before fully committing to active surveillance, because the initial biopsy may have missed something. In one study, 27% of patients initially eligible were upgraded or upstaged on immediate repeat biopsy. The NCCN recommends a confirmatory biopsy within 6 to 24 months of the original (earlier if the first biopsy was done without MRI guidance), and no later than 3 years no matter what.
When Active Surveillance Is Not the Right Choice.
Men with unfavorable intermediate-risk or high-risk cancer and a life expectancy greater than 10 years should generally get definitive treatment.
Active Surveillance and BRCA2.
BRCA2 carriers deserve special mention. A study of 1,211 men on active surveillance found BRCA2 carriers had a 2.74-fold higher chance of grade reclassification than noncarriers. In the IMPACT study, BRCA2 carriers had higher rates of clinically significant prostate cancer (3.1% vs. 1.3%) and more unfavorable disease (65% vs. 32%). Active surveillance is not impossible for BRCA2 carriers, but it requires closer monitoring and a lower threshold to proceed to treatment.
The Emerging Tools.
A few new technologies are starting to refine active surveillance:
MPS2-AS (the urine test) was tested in 330 GG1 patients on active surveillance and outperformed MRI for predicting upgrading. It could potentially avoid 64% of unnecessary biopsies while missing only 3.2% of significant upgrades.
AI-based digital pathology like ArteraAI MMAI and AIRAProstate analyzes biopsy slides and pulls out information that even expert pathologists may miss.
MRI radiomics uses computer analysis of imaging features that humans cannot see.
The NCCN currently treats these as promising but not yet ready to replace standard biopsy and MRI.
Surgery (Radical Prostatectomy)
This means removing the entire prostate gland, usually with robotic assistance.
Pros:
Removes the cancer entirely
Provides definitive staging based on the actual tissue
PSA should drop to undetectable levels afterward
Cons:
Erectile dysfunction affects about 2 in 3 men long term
Urinary incontinence affects about 1 in 5 men long term
Surgical risks include blood loss requiring transfusion (3.6%) and urological infections (3.4%)
Death or organ failure is rare (less than 1%)
Radiation Therapy
Two main types:
External beam radiation therapy (EBRT): High-energy beams aimed at the prostate from outside the body, usually over several weeks.
Brachytherapy: Radioactive seeds placed directly into the prostate. Can be used by itself for low-risk and favorable intermediate-risk disease.
Pros: No surgery. Similar cancer control rates to surgery for most risk groups.
Cons: Bowel irritation (diarrhea, rectal bleeding), urinary symptoms, erectile dysfunction (which develops gradually over months to years rather than right away), and fatigue.
Androgen Deprivation Therapy (ADT): Starving the Cancer
Prostate cancer cells need testosterone to grow, the way a car needs gas. ADT shuts off testosterone production, either through medication or through removing the testicles (orchiectomy).
Types of ADT Medications.
GnRH agonists (leuprolide, goserelin, triptorelin): Injections every 1, 3, or 6 months.
GnRH antagonists (degarelix injection, relugolix pill): Block testosterone production without the initial "testosterone flare" that agonists can cause. Relugolix (Orgovyx) is the first pill option.
Antiandrogens (bicalutamide, flutamide, nilutamide): Block testosterone from reaching cancer cells.
When ADT Is Used.
Combined with radiation for intermediate-risk (4 to 6 months) and high-risk (18 to 36 months) localized disease.
As the foundation of treatment for metastatic disease, usually combined with newer agents.
⚠️ ADT is effective. The side effects are also real, and they reach far beyond sexual function.
Going on ADT means hot flashes (in 60% of men), erectile dysfunction (in over 70%), loss of libido, muscle loss, weight gain, bone loss with measurably higher fracture rates, and increased risk of diabetes and heart attack. Mood changes, depression, and cognitive effects are common. None of this means ADT is the wrong choice — for many men with intermediate-risk, high-risk, or metastatic disease, it's life-prolonging treatment. But the management plan starts the day ADT starts: a baseline DEXA scan for bone density, a cardiovascular risk assessment, and a resistance + aerobic exercise routine that the article calls treatment, not optional. Going into this without that plan is the part to avoid.
Side Effects of ADT.
These are significant and deserve open conversation:
Hot flashes (60% of men)
Erectile dysfunction (more than 70%)
Loss of libido
Weight gain and increased body fat (about 9% increase)
Loss of muscle mass and strength
Bone loss and fractures (19.4% fracture rate with ADT vs. 12.6% without)
Increased risk of diabetes (29.0 vs. 20.9 cases per 1,000 person-years)
Increased risk of heart attack (13.5 vs. 10.9 cases per 1,000 person-years)
Mood changes, depression, and cognitive effects
Gynecomastia (breast enlargement)
Fatigue and anemia
Decreased testicle and penile size
How to Manage ADT Side Effects.
Exercise (both resistance and aerobic) helps with muscle loss, fatigue, weight gain, and mood. This is not optional. It is treatment.
Bone health monitoring: Baseline DEXA scan, calcium (1,000 to 1,200 mg/day from food, not supplements), vitamin D3 (target 30 to 50 ng/mL), and bone-protective medications (denosumab or bisphosphonates) when fracture risk is elevated.
Cardiovascular risk management: Blood pressure control, lipid management, glucose monitoring. A cardiology referral may be wise for higher-risk patients.
Hot flash treatments: Venlafaxine, gabapentin, or medroxyprogesterone can help.
Gynecomastia prevention: Tamoxifen or low-dose preventive radiation to the breast area.
Newer Treatments for Advanced Disease
For metastatic prostate cancer, ADT alone is no longer enough. Current guidelines strongly recommend combining ADT with one of the following:
Androgen receptor pathway inhibitors (ARPIs): Abiraterone (Zytiga), enzalutamide (Xtandi), apalutamide (Erleada), or darolutamide (Nubeqa). These drugs block androgen signaling even more completely. Abiraterone plus ADT improved overall survival from 36.5 months to 53.3 months compared to ADT alone in one major trial.
Docetaxel chemotherapy: May be added to ADT plus an ARPI for men with high-volume metastatic disease.
For men with BRCA2 mutations: Niraparib plus abiraterone is an option.
Food Effects on Medications
🚫 If you take abiraterone (Zytiga), do not take it with food.
The standard formulation must be taken on an empty stomach — no food for 2 hours before or 1 hour after the dose. Taking it with food dramatically increases absorption (up to ten times higher with a high-fat meal) and can cause dangerous side effects, including severe hypertension, low potassium, fluid retention, and liver toxicity. If the standard 1,000 mg dose is unaffordable, a different protocol exists — a reduced 250 mg dose with a low-fat breakfast — but that's a deliberate prescriber decision, not something to improvise. Set a reminder, time it around your day, and treat the empty-stomach rule as part of the medication itself.
Abiraterone (standard formulation): Must be taken on an empty stomach. No food for 2 hours before or 1 hour after. Taking it with food dramatically increases absorption and can cause dangerous side effects. However, a reduced dose of 250 mg/day with a low-fat breakfast can be used if the standard 1,000 mg/day dose is too expensive.
Enzalutamide, apalutamide, darolutamide: Can be taken with or without food.
Relugolix: Can be taken with or without food.
Part Nine: How to Recognize Warning Signs in Yourself
Prostate cancer does not announce itself with a megaphone. But here are reasons to talk to a doctor:
You are over 45 (or over 40 if Black, have a family history, or carry a known genetic risk) and have never discussed PSA screening.
You notice changes in urination: weaker stream, getting up multiple times at night, trouble starting or stopping.
You see blood in your urine or semen.
You develop new, unexplained bone pain, especially in the back, hips, or pelvis.
You have unexplained weight loss or fatigue.
A family member (father, brother, or even a mother or sister with BRCA mutations) was diagnosed with prostate, breast, ovarian, or pancreatic cancer.
Remember, most of these symptoms are more likely to be something benign. But "probably nothing" is not a diagnosis. Getting checked is the smart move.
Part Ten: How to Talk About It
Prostate cancer conversations can feel uncomfortable. The exam involves a finger and a rectum. The treatments can affect sexual function and bladder control. This is intimate territory.
For Patients
It is okay to feel awkward. Doctors have these conversations every day.
Write down your questions before the appointment.
Bring a partner or trusted person for support and to help remember what was said.
Ask about ALL options, including active surveillance. Not every cancer needs immediate treatment.
Ask the question that cuts through everything else: "If this were your prostate, what would you do?" Doctors are people too, and the answers can be illuminating.
For Family Members
If your dad or brother is going through this, the most useful thing you can do is show up. Offer to drive to appointments. Help with the question list. Sit through the awkward conversations. The numbers on cancer outcomes look better when people are not facing them alone.
For Doctors
Use plain language. "We are going to check your PSA with a blood test" beats medical jargon.
Normalize the conversation. "This is something we discuss with all men your age."
Present balanced information. Do not just order a PSA without explaining what it means.
Discuss quality of life openly, including sexual function, urinary control, and emotional well-being.
Part Eleven: Living with It and Making Peace with It
This is the part nobody puts in a textbook, and it matters anyway.
A Diagnosis Is Not a Death Sentence
The five-year survival rate for localized disease is essentially 100%. Even for men with metastatic disease, modern treatments have dramatically extended survival. A prostate cancer diagnosis in 2026 is not the same diagnosis it would have been in 1996. Treatments have transformed.
You Can Make Friends With Active Surveillance
For many men, the hardest part of low-risk prostate cancer is being told "we are not going to treat it." That can feel like being told "we know your house has a leak but we are not going to fix it." It is not actually that. It is more like "your house has a tiny drip that has not done any damage in years, and the repair is expensive and messy, so we are going to keep an eye on it and only act if it grows." Active surveillance is real medical care. The studies are clear that most men on it do well.
You Can Enjoy Life After Treatment
Many men, even after radical prostatectomy or radiation, return to full lives. Erectile dysfunction is common after treatment, but it is treatable. Pelvic floor exercises help with incontinence. Sex therapy and couples counseling help with the emotional adjustment. The men who do best are the ones who treat recovery as an active project rather than something that just happens to them.
You Can Be Honest About the Hard Parts
Some treatments leave permanent changes. ADT, in particular, can dramatically change mood, energy, body composition, and sexual function. Pretending those changes are not happening makes them worse. Talking about them with your doctor, your partner, and ideally a therapist who knows the territory makes them easier.
You Can Use This as a Reason to Get Healthier
A lot of men who go through prostate cancer treatment come out the other side with much better lifestyle habits. Exercise, diet, weight loss, smoking cessation: all of these help with both cancer outcomes and the side effects of treatment. They also reduce the risk of heart disease, which, as a reminder, kills more men with prostate cancer than the cancer itself.
You Can Find a Community
Support groups (in person and online) exist specifically for prostate cancer. Talking to other men who have been through it can do things that medical literature cannot.
Part Twelve: Myths That Need to Retire
Myth: "A high PSA means I have cancer." Reality: PSA can be elevated by BPH, prostatitis, recent sex, recent bike riding, and a long list of other things. A single high PSA always deserves a repeat test before anyone talks about biopsy.
Myth: "If I have prostate cancer, I need surgery right away." Reality: Most low-risk prostate cancers can be safely watched with active surveillance. Rushing to surgery for a slow-growing cancer is often worse than the cancer.
Myth: "PSA screening always saves lives." Reality: PSA screening reduces prostate cancer deaths but does not appear to reduce overall deaths from all causes. It is a real tool with real benefits and real harms. The decision to screen deserves a real conversation.
Myth: "Prostate cancer is an old man's disease, so younger men can ignore it." Reality: Mostly true, but with important exceptions. Black men, men with a family history, and men with BRCA mutations can develop it earlier and more aggressively. Knowing your risk profile matters.
Myth: "If I take finasteride for hair loss, I do not need to worry about PSA." Reality: Finasteride cuts PSA by about 50%. A PSA that looks normal while on finasteride could actually be twice as high in real terms. Tell your doctor about every medication.
Myth: "Vitamins and supplements can prevent prostate cancer." Reality: The SELECT trial showed that vitamin E and selenium do not prevent prostate cancer, and vitamin E may slightly raise the risk. Save your money.
Myth: "If treatment caused erectile dysfunction, there is nothing to be done." Reality: ED after prostate cancer treatment is one of the most treatable kinds of ED. PDE5 inhibitors, injections, vacuum devices, and penile implants all work. Pelvic floor therapy helps. Mental health support helps. There are options.
Myth: "Men who have had their prostate removed cannot have orgasms anymore." Reality: Orgasm is possible after prostatectomy, though it changes. Specifically, there is no ejaculation (the fluid producers are gone), but the sensation can still happen. Sex therapists who specialize in cancer survivorship are an underused resource.
The Bottom Line
Prostate cancer is common, but it is not the dramatic killer many men imagine. The most important things any man can do are:
Know the risk factors (age, family history, race, BRCA).
Have the screening conversation at the right age, ideally well before symptoms appear.
Make a shared, informed decision about PSA testing.
If diagnosed, understand that low-risk cancer often does not need immediate treatment.
If treatment is needed, choose a multidisciplinary team (urologist, radiation oncologist, medical oncologist) and discuss every option.
Eat well, move often, maintain a healthy weight, and do not smoke. These habits help prevent prostate cancer, reduce treatment side effects, and protect the heart.
Your prostate is small. The decisions around it are not. Take them seriously, but do not be ruled by fear. The science has moved forward enormously in the last decade, and most men with prostate cancer will not die from it. The job is to be the kind of man who pays attention, asks questions, and partners with good medical people to make smart choices.
That is not paranoia. That is just being your own best advocate.
This article is for general education and isn't medical advice. PSA screening is a shared decision between you and a doctor who knows your history — not a one-size-fits-all algorithm. If you have a family history of prostate, breast, ovarian, or pancreatic cancer, mention it; BRCA mutations change the calculus. If you take finasteride, dutasteride, or any 5-alpha reductase inhibitor (including for hair loss), tell every doctor who orders a PSA — a "normal" result on those drugs may not be normal at all. If you've been diagnosed, the right call depends on the risk group, your life expectancy, and your priorities; a multidisciplinary team (urology, radiation oncology, medical oncology) is the standard of care for treatment decisions.